Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May-Jun;35(3):1365-1377.
doi: 10.21873/invivo.12389. Epub 2021 Apr 28.

Radiotherapy and Renal Cell Carcinoma: A Continuing Saga

Despoina Spyropoulou  1 , Panagiotis Tsiganos  2 , Foteinos-Ioannis Dimitrakopoulos  3   4 , Maria Tolia  5 , Angelos Koutras  3 , Dimitris Velissaris  6 , Maria Lagadinou  7 , Nikolaos Papathanasiou  8 , Areti Gkantaifi  9 , Haralabos Kalofonos  3 , Dimitrios Kardamakis  10
Affiliations
Review

Radiotherapy and Renal Cell Carcinoma: A Continuing Saga

Despoina Spyropoulou et al. In Vivo. 2021 May-Jun.

Abstract

Renal cell carcinoma (RCC) is one of the most aggressive malignancies of the genito-urinary tract, having a poor prognosis especially in patients with metastasis. Surgical resection remains the gold standard for localized renal cancer disease, with radiotherapy (RT) receiving much skepticism during the last decades. However, many studies have evaluated the role of RT, and although renal cancer is traditionally considered radio-resistant, technological advances in the RT field with regards to modern linear accelerators, as well as advanced RT techniques have resulted in breakthrough therapeutic outcomes. Additionally, the combination of RT with immune checkpoint inhibitors and targeted agents may maximize the clinical benefit. This review article focuses on the role of RT in the therapeutic management of renal cell carcinoma.

Keywords: Renal cell cancer; oligometastatic disease; radioresistance; radiosensitivity; radiotherapy; review; stereotactic body radiation therapy.

PubMed Disclaimer

Conflict of interest statement

None to be declared.

References

    1. Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013;7:139–148. doi: 10.2147/BTT.S32958. - DOI - PMC - PubMed
    1. Chow WH, Devesa SS. Contemporary epidemiology of renal cell cancer. Cancer J. 2008;14(5):288–301. doi: 10.1097/PPO.0b013e3181867628. - DOI - PMC - PubMed
    1. Qayyum T, Oades G, Horgan P, Aitchison M, Edwards J. The epidemiology and risk factors for renal cancer. Curr Urol. 2013;6(4):169–174. doi: 10.1159/000343534. - DOI - PMC - PubMed
    1. Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng D, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primer. 2017;3(1):1–19. doi: 10.1038/nrdp.2017.9. - DOI - PMC - PubMed
    1. O’Toole KM, Brown M, Hoffmann P. Pathology of benign and malignant kidney tumors. Urol Clin North Am. 1993;20(2):193–205. - PubMed

MeSH terms

LinkOut - more resources